Digital Health Funding Summary
This Week in Digital Health
Unlocking the future of healthcare. An insider's guide to game-changing digital innovations.
Total Funding Raised
The total amount raised across all reported deals this week is approximately $741.95 million.
Top Deals
News
Amolyt Pharma , an Ecully, France global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, announced that its previously announced acquisition by global pharmaceutical company 阿斯利康 (LSE/STO/Nasdaq: AZN), has closed.
#DigitalHealth Venture Investment Rises, but Many Deals Have Yet to Pay Off. WSJ
Funding
Element Biosciences , a San Diego-based company specializing in scientific technology development, has raised over $277 million in a Series D funding round. This latest investment brings the company's total funding to over $680 million. The round was led by Wellington Management, with participation from new and existing investors, including Samsung Electronics, Fidelity, Foresite Capital, T. Rowe Price Associates, Inc, and Venrock. Element Biosciences plans to use the funds to support the commercialization of its benchtop DNA sequencer, AVITI?, and to prepare for the launch of AVITI24?. This innovative instrument integrates sequencing and cyto-profiling capabilities into a single biology platform.
HarmonyCares , a Troy, Michigan-based company offering value-based in-home longitudinal care, has secured a substantial $200 million in funding. The investment round was spearheaded by General Catalyst, McKesson Ventures, and an unnamed national payor, with additional participation from K2 HealthVentures and existing investors, including Rubicon Founders, Valtruis, HLM Capital, and Oak HC/FT. With this significant capital injection, HarmonyCares plans to broaden its geographical reach and invest in new technology development. The company aims to enhance its ability to deliver improved clinical outcomes and patient satisfaction on a larger scale, further solidifying its position in the value-based healthcare sector.
Beacon Therapeutics , a London-based ophthalmic gene therapy company, has successfully raised $170 million in Series B funding, bringing the company's total funding to $290 million. The investment was led by Forbion, with additional participation from Syncona Limited, Oxford Science Enterprises, and the University of Oxford. Initial investments also came from TCGX and Advent Life Sciences.
SciRhom , a Munich-based biopharmaceutical company specializing in developing therapeutic iRhom2 antibodies, has raised €63 million in Series A funding. The investment round was co-led by a group of prominent venture capital firms, including Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners. New investor Bayern Kapital joined the round, and existing investors High-Tech Gründerfonds (HTGF) and PhiFund Ventures from New York. With this substantial funding, sciRhom aims to accelerate and expand the scope of its therapeutic strategy in treating autoimmune disorders. This investment underscores the potential of sciRhom's innovative approach to addressing unmet medical needs in autoimmune diseases.
Regard , an AI-powered clinical insights platform based in Los Angeles, has secured $61 million in Series B funding. The investment round was spearheaded by Oak HC/FT, with additional support from Cedars-Sinai Health Ventures and existing investors TenOneTen Ventures, Calibrate Ventures, and Techstars. The company plans to utilize this capital to enhance its core clinical insights platform, further research in large language models (LLMs), and broaden its reach beyond inpatient facilities. This funding injection aims to accelerate Regard's product development and expansion efforts in the healthcare technology sector.
Octagos Health, Inc. , a Houston-based company specializing in AI-driven cardiac device monitoring solutions, has raised over $43 million in Series B funding. The investment round was led by Morgan Stanley Expansion Capital, with additional participation from Mucker Capital and other strategic investors. This significant capital infusion will accelerate enhancements to Octagos Health's platform, which likely involves improving its AI capabilities and expanding its cardiac monitoring features. Additionally, the company plans to scale up its commercial team and operations, suggesting a push for market expansion and increased adoption of its technology. This funding round underscores investor confidence in Octagos Health's innovative approach to cardiac care and positions the company for substantial growth in the digital health and medical device monitoring sectors.
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., collectively known as AusperBio , a clinical-stage biotech company operating in the USA and China, has successfully closed a $37 million Series A financing round. The funding was spearheaded by existing investor InnoPinnacle Fund, with new investors, including Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital, joining the round. AusperBio plans to use this capital to further the clinical development of its lead product candidate, AHB-137, as well as to advance its proprietary Med-Oligo? technology platform and expand its product pipeline.
Adona Medical, a Los Gatos, California-based Shifamed portfolio company focused on heart failure solutions, has secured $33.5 million in Series C funding. The round was led by Cormorant Asset Management and TCP Health Ventures, with participation from several other investors, including Excelestar Ventures, PA MedTech VC Fund II, and Unorthodox Ventures. Adona's key innovation is an interatrial shunt featuring an adaptable flow channel that can be adjusted post-implantation using a proprietary induction catheter. The company plans to use this capital to advance its product development and initiate clinical trials of its adjustable interatrial shunt, incorporating integrated bi-atrial pressure monitoring. This funding represents a significant step forward for Adona Medical in its mission to develop novel technologies for addressing heart failure, potentially offering new treatment options for patients with this challenging condition.
领英推荐
NOWDiagnostics | NOWDx , based in Springdale, Arkansas, has successfully raised $22.5 million in a Series B funding round. The company develops over-the-counter (OTC) and point-of-care (POC) diagnostic tests. This funding round was led by DigitalDx Ventures, with participation from Labcorp Venture Fund and Kompass Kapital Management. NOWDx plans to utilize this capital to accelerate the commercialization of its at-home diagnostic tests. Further, its diagnostic innovation efforts expand its test pipeline and support strategic hiring initiatives. This investment signals strong confidence in NOWDx's potential to advance accessible diagnostic solutions in the healthcare market.
AIRS Medical , a Seoul-based company focusing on AI and robotics for healthcare, has successfully raised $20 million in Series C funding. BSK Investment and Shinyoung Securities led the investment round. With this new capital, AIRS Medical plans to enhance its SwiftMR product development, expand its international market presence, invest in research and development, and work towards improving patient outcomes globally. This funding round highlights the growing interest in AI-driven healthcare solutions and positions AIRS Medical to further innovate in medical technology.
Courier Health , a New York City-based technology company focusing on chronic conditions and rare diseases, has raised $16.5 million in Series A funding. Norwest Venture Partners led the investment round, which included additional participation from existing investor Work-Bench.
HepaRegeniX GmbH , a clinical-stage company based in Tuebingen, Germany, has successfully raised €15 million in Series C funding to advance its innovative regenerative therapy for acute and chronic liver diseases. The investment round was led by Vesalius Biocapital IV, with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds (HTGF). This substantial funding will primarily accelerate the clinical development of HepaRegeniX's lead candidate, HRX-215. The investment underscores the potential of HepaRegeniX's approach in addressing unmet needs in liver disease treatment and positions the company to make significant strides in bringing its novel therapy closer to patients who could benefit from regenerative liver treatments.
Velentium , a Houston-based engineering firm specializing in medical device design and manufacturing, has secured $15 million in growth financing from Trinity Capital (NASDAQ: TRIN). The company plans to utilize these funds to expand its operations and enhance its development initiatives, signaling a significant step forward in its growth trajectory within the medical technology sector.
Bedal International, a medical device company based in Diepenbeek, Belgium, specializing in advanced catheter securement solutions, has secured $11 million in funding. The round was led by White Fund and SFPIM (Belgium's sovereign wealth fund), with additional participation from F3Finance, LRM, and Bedal's management team. The company plans to use this capital to expand its operations and boost commercial efforts, focusing on growing its presence in the US market.
Endoron Medical , a Tel Aviv-based medtech company, has secured $10 million in Series A funding. The company specializes in endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms. Sofinnova Partners led the investment round, with additional participation from the European Innovation Council Fund (EIC Fund).
Dioseve , a Tokyo-based company specializing in assisted reproductive technology using oocytes derived from iPS cells, has raised $7 million in funding. This round involved several investors, including Spiral Capital, Archetype Ventures, ANRI, ASKA Pharmaceutical Co., DG Daiwa Ventures, Future Venture Capital Co., QR Investment, and two unnamed investors. This latest investment brings Dioseve's total funding to approximately $10 million. The company plans to utilize these funds to further its research and development efforts and expand its workforce, focusing on global expansion. This investment underscores the potential of Dioseve's innovative approach to reproductive technology, particularly its work with iPS cell-derived oocytes, and positions the company for growth in the international market.
Spotlight Medical , a Paris-based startup, has secured €6.2 million in Seed funding to advance its AI-driven prognosis tests for precision medicine. Kurma Partners and Heal Capital led the funding round. Led by CEO Sylvain Berlemont, the company leverages decades of patient data to develop AI tests that improve treatment selection, aiming to provide personalized and effective care that enhances patient outcomes and quality of life. Spotlight Medical plans to use the funds to bring its first prognosis test to clinical use, marking a significant step in the commercialization of AI-based solutions for cancer treatment.
Heidelberg Epignostix GmbH , a precision cancer diagnostics startup based in Heidelberg, Germany, has secured €4.3 million in Seed funding. The investment round was led by CARMA FUND I Capital GmbH & Co KG, with additional support from High-Tech Gründerfonds, LBBW Venture Capital GmbH, and Start-up BW Seed Fonds. The company plans to utilize this capital to accelerate the development of its primary diagnostic tool, which focuses on brain tumor classification. This funding will enable Heidelberg Epignostix to advance its technology in precision oncology further, potentially improving diagnostic accuracy and treatment outcomes for brain cancer patients.
Pan Cancer T , a biotech startup based in Rotterdam, the Netherlands, has secured €4.25 million in Seed extension funding, bringing its total funding to approximately €11 million. The round was led by InnovationQuarter, with participation from existing investors Van Herk Ventures, Thuja Capital, Swanbridge Capital, and Erasmus MC O&O Holdings. This investment will enable Pan Cancer T to complete preclinical studies for its lead TCR-T cell product, PCT1:CO-STIM, and advance its CMC activities, creating value and reducing project risks. Additionally, the funding will support the progression of earlier-stage pipeline projects targeting colorectal and ovarian cancers and the development of a second next-generation engineering approach. As part of this funding round, Nina Satih from InnovationQuarter will join as a Supervisory Board observer, further strengthening the company's governance and strategic guidance in its mission to develop innovative T-cell therapies for solid cancer treatment.
Biostate AI , a Palo Alto-based startup specializing in scalable biodata foundry technology, has secured $4 million in funding. Matter Venture Partners led the investment round, which included contributions from several other venture capital firms and notable individuals in the tech and biotech industries. Among the participants were Vision Plus Capital, Catapult VC, the Caltech Seed Fund, and executives from companies like Anthropic, Rescale, 10X Genomics, and Twist Bioscience.
Maximum Fidelity Surgical Simulations (MaxFi) (Maximum Fidelity Surgical Simulations), a St. Louis-based company specializing in creating lifelike cadavers for highly realistic surgical simulations in medical education, has secured $2.25 million in Seed funding. The investment round was spearheaded by St. Louis Arch Angels, with participation from BioGenerator Ventures and Missouri Technology Corporation (MTC). With this new capital injection, MaxFi aims to broaden its operations and intensify its development initiatives, potentially revolutionizing the field of medical training through advanced simulation technologies.
Roga , a neurotech and mental healthcare startup based in Los Angeles, has secured $1.2 million in Pre-Seed funding to support the launch of their wearable device designed to address chronic stress and burnout. The funding round attracted a diverse group of investors, including venture capital firms such as Exceptional Ventures, ODX by On Deck, and Minded Ventures, as well as institutional backers like The Centre for Aging + Brain Health Innovation (CABHI) and the Ontario Brain Institute. Additionally, the AngelList Fund participated, along with individual angel investors, notably senior directors from tech giants Samsung and Google. This investment will enable Roga to bring its innovative stress-reduction technology to market, potentially offering a new solution in the growing field of mental health and wellness.
UBERDOC, Inc. , a Boston-based healthcare platform provider, has received an undisclosed investment from CharmHealth and Bioverge. The company plans to use this new funding to fuel its growth strategy, focusing on expanding its network of doctors and geographical reach. This expansion aims to enhance Uberdoc's ability to connect patients with optimal healthcare providers more quickly and efficiently. While the exact investment amount remains undisclosed, this funding round underscores investor confidence in Uberdoc's mission to streamline patient-provider connections in the healthcare sector.
Heartbeat Health, a New York City-based cardiovascular care company, has received a significant growth investment from Cressey & Company. While the exact amount was not disclosed, the funding round also saw participation from existing investors, including .406 Ventures, Echo Ventures, Kindred Ventures, and Optum Ventures. This influx of capital will be strategically utilized to enhance Heartbeat Health's clinical offerings and strengthen its care team. Additionally, the company plans to expand its reach to more customers across the United States, accelerating its growth trajectory. This investment underscores the growing importance of innovative healthcare solutions in the cardiovascular sector and positions Heartbeat Health to potentially become a more prominent player in the digital health landscape, particularly in heart-related care services.
ProofPilot , a New York City-based company providing a clinical experience platform (CXP), has secured an undisclosed amount in Series C funding. The investment round was led by Sopris Capital, with participation from Mitsui & Co. (U.S.A.), Inc. While the exact amount remains undisclosed, this funding represents a significant vote of confidence in ProofPilot's technology and market potential. The company plans to utilize this fresh capital to expand its operations and extend its business reach, likely aiming to enhance its platform capabilities and increase its market share in the clinical research technology sector. This investment could potentially accelerate ProofPilot's growth and strengthen its position as a key player in streamlining and improving clinical trial experiences.